X

Xenon Pharmaceuticals Inc
NASDAQ:XENE

Watchlist Manager
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Watchlist
Price: 43.44 USD -0.18% Market Closed
Market Cap: 3.3B USD

Xenon Pharmaceuticals Inc
Cash from Operating Activities

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Xenon Pharmaceuticals Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Cash from Operating Activities
-$252m
CAGR 3-Years
-43%
CAGR 5-Years
-75%
CAGR 10-Years
-32%
Theratechnologies Inc
TSX:TH
Cash from Operating Activities
$7m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Repare Therapeutics Inc
NASDAQ:RPTX
Cash from Operating Activities
-$70.1m
CAGR 3-Years
N/A
CAGR 5-Years
-95%
CAGR 10-Years
N/A
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Cash from Operating Activities
$120.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Willow Biosciences Inc
TSX:WLLW
Cash from Operating Activities
-CA$2.2m
CAGR 3-Years
51%
CAGR 5-Years
29%
CAGR 10-Years
N/A
Spectral Medical Inc
TSX:EDT
Cash from Operating Activities
-CA$9.1m
CAGR 3-Years
2%
CAGR 5-Years
-115%
CAGR 10-Years
0%
No Stocks Found

Xenon Pharmaceuticals Inc
Glance View

Market Cap
3.4B USD
Industry
Biotechnology

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company spotlighted in the arena of precision medicine, with a strategic emphasis on neurological disorders. The company finds its roots in the ethos of innovation, aiming to transform the landscape of treatment through the development of novel therapeutics. At the heart of its operations is a robust platform driven by genetic insights, which allows the company to unearth underlying neurological pathways, thereby targeting diseases that truly lack effective treatment options. Xenon leverages its deep expertise in ion channel biology—vastly important in the function of the nervous system—to design small molecule therapies, positioning itself as a pioneer in addressing complex cerebral disorders such as epilepsy. A key aspect of how Xenon Pharmaceuticals generates revenue is through a dual approach: self-initiated proprietary product development and strategic collaborations with established pharmaceutical giants. Its revenue model is largely propelled by both developmental milestone payments and potential royalties from these alliances. This includes partnerships that allow Xenon to share its innovative platform while receiving financial backing and resources, ensuring the infrastructural strength needed to sustain its clinical programs. By maintaining a pipeline that promises targeted, personalized treatments, Xenon aims not only to meet clinical milestones but to also carve out significant market share within the neuroscience domain, paving its path to profitability and industry impact.

XENE Intrinsic Value
8.86 USD
Overvaluation 80%
Intrinsic Value
Price
X

See Also

What is Xenon Pharmaceuticals Inc's Cash from Operating Activities?
Cash from Operating Activities
-252m USD

Based on the financial report for Sep 30, 2025, Xenon Pharmaceuticals Inc's Cash from Operating Activities amounts to -252m USD.

What is Xenon Pharmaceuticals Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-32%

Over the last year, the Cash from Operating Activities growth was -55%. The average annual Cash from Operating Activities growth rates for Xenon Pharmaceuticals Inc have been -43% over the past three years , -75% over the past five years , and -32% over the past ten years .

Back to Top